Clinical Trial Update: Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss [Phase 2]

View source ↗

Summary

An update on a Phase 2 safety study of an Agouti-related Protein (AgRP) inhibitor for obesity, with the trial status showing completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• AgRP inhibitor

Snippet

Sponsor: vTv Therapeutics | Conditions: Obesity | Phase 2 | Status: COMPLETED